PAR 1.69% 29.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-1071

  1. 9,674 Posts.
    lightbulb Created with Sketch. 1232
    TGA (and early sales) is not the near term catalyst any longer given the proposed trial design has been developed to ensure all governing bodies are comfortable and then get on board. That's why we're flatlining in the $2s as the market resets it's expectations. PR will as a result likely become increasingly uncomfortable with the market's ongoing treatment of PAR and look to force the issue via a deal later this year. All IMO of course......and that it won't really matter if we receive such news in CY21 or CY22 but it is coming.

    p.s. I'm sure PR will see Bell Potter's price target as somewhat underwhelming despite Coppo's personal call.





 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.